The drug, intended for the treatment of type 2 diabetes, became popular for its effectiveness in losing weight and reported a new secondary benefit.
A study revealed that Ozempic, medicine to treat type 2 diabetes and which was popularized for its high effectiveness in losing weight, could have another secondary benefit: helping to reduce the risk of developing Alzheimer’s.
The investigation was carried out by the Cleveland University of Medicine, Ohiotaking into account the electronic health records of approximately one million Americans with the illness during the last three years.
According to the results of the study, published in the journal Alzheimer’s & Dementiatreatment with semaglutide, the component of Ozempic, can reduce 40% to 70% chance of an initial diagnosis of Alzheimer’s.
The teacher Rong Xuleader of the research team, commented that these results provide “real evidence of its impact on Al disease.”zheimer.” He also noted that, although the effects positive neuroprotectors of semaglutide surprised even researchers“it is necessary to continue research through randomized clinical trials.”
The B side of Ozempic, the fashionable drug for weight loss
The fever from weight loss medicationslike the Ozempicunleashed a wave of miracle products and diets that promise quick and easy results. However, experts from harvard warn that this trend It is putting the health of millions of people at risk.
According to S. Bryn Austin of the Harvard School of Public Health, “the diet culture-driven frenzy around Ozempic basically poured gasoline on the fire of the garbage containers of predatory industries“. The desperate quest to lose weight has led to an increase in the sale of dubious supplements, laxatives and ultra-processed products disguised as healthy.
The high price of medications such as Ozempic generated a black market for imitations and dangerous compounds. Furthermore, social pressure to have a thin body led many people to look for quick and unhealthy solutions.
The food industry benefited from this new trend. Upon identifying a new business opportunity in weight loss medications, they developed ultra-processed products aimed at this market, thus perpetuating the cycle of obesity.
Source: Ambito
